Synthesis, Chemical Characterization, and Biological Evaluation of Hydrophilic Gold(I) and Silver(I) N-Heterocyclic Carbenes as Potential Anticancer Agents

A series of new gold(I) and silver(I) N-heterocyclic carbenes bearing a 1-thio-β-d-glucose tetraacetate moiety was synthesized and chemically characterized. The compounds' stability and solubility in physiological conditions were investigated employing a multitechnique approach. Interaction studies with biologically relevant proteins, such as superoxide dismutase (SOD) and human serum albumin (HSA), were conducted via UV-vis absorption spectroscopy and high-resolution ESI mass spectrometry. The biological activity of the compounds was evaluated in the A2780 and A2780R (cisplatin-resistant) ovarian cancer cell lines and the HSkMC (human skeletal muscle) healthy cell line. Inhibition studies of the selenoenzyme thioredoxin reductase (TrxR) were also carried out. The results highlighted that the gold complexes are more stable in aqueous environment and capable of interaction with SOD and HSA. Moreover, these carbenes strongly inhibited the TrxR activity. In contrast, the silver ones underwent structural alterations in the aqueous medium and showed greater antiproliferative activity.

Synthesis of a Novel Gold(I) Complex and Evaluation of Its Anticancer Properties in Breast Cancer Cells

BACKGROUND

Platinum complexes are commonly used for cancer chemotherapy; however, they are not only highly-priced but also have various side effects. It is, therefore, important to design affordable anticancer drugs with minimal side effects.

METHODS

We synthesized a new gold(I) complex, PF6{(BDPEA)(TPPMS) digold(I)} (abbreviated as PBTDG) and tested its cytotoxicity in MCF-7 breast cancer cells. We also evaluated the effects of PBTDG on mitochondrial membrane potential, generation of reactive oxygen species (ROS) and apoptosis in breast cancer cells.

RESULTS

The IC50 values for PBTDG and sorafenib were found to be 1.48 μM and 4.45 μM, respectively. Exposure to PBTDG caused significant and concentration-dependent depletion of ATP and disruption of mitochondrial membrane potential. PBTDG induced 2.6, 3.6, and 5.7-fold apoptosis for 1 μM, 3 μM, and 10 μM concentrations, respectively. The induction of apoptosis by the same concentrations of sorafenib was 1.2, 1.3, and 1.6-fold, respectively. The low concentration of PBTDG (1 μM) induced the generation of ROS by 99.83%, which was significantly higher than the ROS generation caused by the same concentration of sorafenib (73.76%). The ROS induction caused by higher concentrations (5 μM) of PBTDG and sorafenib were 104.95% and 122.11%, respectively.

CONCLUSION

The lower concentration of PBTDG produced similar cytotoxicity and apoptotic effects that were caused by a comparatively higher concentration of known anticancer drug (sorafenib). The anticancer effects of PBTDG are attributed to its tendency to disrupt mitochondrial membrane potential, induction of apoptosis and generation of ROS. Further studies are warranted to test the anticancer effects of PBTDG in animal models of cancer.

Recent development of gold(I) and gold(III) complexes as therapeutic agents for cancer diseases

Metal complexes have demonstrated significant antitumor activities and platinum complexes are well established in the clinical application of cancer chemotherapy. However, the platinum-based treatment of different types of cancers is massively hampered by severe side effects and resistance development. Consequently, the development of novel metal-based drugs with different mechanism of action and pharmaceutical profile attracts modern medicinal chemists to design and synthesize novel metal-based agents. Among non-platinum anticancer drugs, gold complexes have gained considerable attention due to their significant antiproliferative potency and efficacy. In most situations, the gold complexes exhibit anticancer activities by targeting thioredoxin reductase (TrxR) or other thiol-rich proteins and enzymes and trigger cell death via reactive oxygen species (ROS). Interestingly, gold complexes were recently reported to elicit biochemical hallmarks of immunogenic cell death (ICD) as an ICD inducer. In this review, the recent progress of gold(I) and gold(III) complexes is comprehensively summarized, and their activities and mechanism of action are documented.

Application of the Redox-Transmetalation Procedure to Access Divalent Lanthanide and Alkaline-Earth NHC Complexes*

Divalent lanthanide and alkaline-earth complexes supported by N-heterocyclic carbene (NHC) ligands have been accessed by redox-transmetalation between air-stable NHC-AgI complexes and the corresponding metals. By using the small ligand 1,3-dimethylimidazol-2-ylidene (IMe), two series of isostructural complexes were obtained: the tetra-NHC complexes [LnI2 (IMe)4 ] (Ln=Eu and Sm) and the bis-NHC complexes [MI2 (IMe)2 (THF)2 ] (M=Yb, Ca and Sr). In the former, distortions in the NHC coordination were found to originate from intermolecular repulsions in the solid state. Application of the redox-transmetalation strategy with the bulkier 1,3-dimesitylimidazol-2-ylidene (IMes) ligand yielded [SrI2 (IMes)(THF)3 ], while using a similar procedure with Ca metal led to [CaI2 (THF)4 ] and uncoordinated IMes. DFT calculations were performed to rationalise the selective formation of the bis-NHC adduct in [SrI2 (IMe)2 (THF)2 ] and the tetra-NHC adduct in [SmI2 (IMe)4 ]. Since the results in the gas phase point towards preferential formation of the tetra-NHC complexes for both metal centres, the differences between both arrangements are a result of solid-state effects such as slightly different packing forces.

Coinage Metal N-Heterocyclic Carbene Complexes: Recent Synthetic Strategies and Medicinal Applications

New weapons are constantly needed in the fight against cancer. The discovery of cisplatin as an anticancer drug prompted the search for new metal complexes. The successful history of cisplatin motivated chemists to develop a plethora of metal-based molecules. Among them, metal-N-heterocyclic carbene (NHC) complexes have gained significant attention because of their suitable qualities for efficient drug design. The enhanced applications of coinage metal-NHC complexes have encouraged a gradually increasing number of studies in the fields of medicinal chemistry that benefit from the fascinating chemical properties of these complexes. This review aims to present recent developments in synthetic strategies and medicinal applications of copper, silver and gold complexes supported by NHC ligands.

N-heterocyclic carbene-metal complexes as bio-organometallic antimicrobial and anticancer drugs, an update (2015–2020)

N-heterocyclic carbenes (NHCs) are organic compounds that typically mimic the chemical properties of phosphines. NHCs have made a significant impact on the field of coordination and organometallic chemistry because they are easy to prepare and handle and because of their versatility and stability. Importantly, the physicochemical properties of NHCs can be easily fine-tuned by simple variation of substituents on the nitrogen atoms. Over the past few years, various NHC–metal complexes have been extensively used as metal-based drug candidates and catalysts (homogeneous or heterogeneous) for various applications. To help assist future work with these compounds, this review provides a thorough review on the latest information involving some biomedical applications of NHC–metal complexes. Specifically, this article focuses on recent advances in the design, synthesis, characterization and biomedical applications (e.g., antimicrobial and anticancer activity) of various NHC–metal complexes (metal: silver, gold, palladium, rhodium, ruthenium, iridium and platinum) covering work published from 2015 to 2020. It is hoped that the promising discoveries to date will help accelerate studies on the encouraging potential of NHC–metal complexes as a class of effective therapeutic agents.

Synthesis, characterization and biological activity of bromido[3-ethyl-4-aryl-5-(2-methoxypyridin-5-yl)-1-propyl-1,3-dihydro-2H-imidazol-2-ylidene]gold(i) complexes

Bromido[3-ethyl-4-aryl-5-(2-methoxypyridin-5-yl)-1-propyl-1,3-dihydro-2H-imidazol-2-ylidene]gold(i) complexes (8a-h) with methoxy, methyl and fluorine substituents at different positions of the 4-aryl ring were synthesized and characterized. The relevance of the 2-methoxypyridin-5-yl residue and the substituents at the 4-aryl ring with regard to the activity against a series of cell lines was determined. Particularly against the Cisplatin-resistant ovarian cancer cell line A2780cis, the most active bromido[3-ethyl-4-(4-methoxyphenyl)-5-(2-methoxypyridin-5-yl)-1-propyl-1,3-dihydro-2H-imidazol-2-ylidene]gold(i) complex 8c was more active than Auranofin. It also inhibited thioredoxin reductase more effectively and induced high amounts of reactive oxygen species in A2780cis cells. Furthermore, its influence on non-cancerous SV 80 lung fibroblasts was lower than that of Auranofin. This fact, together with a high accumulation rate in tumor cells, determined on the example of MCF-7 cells, makes this complex an interesting candidate for further extensive studies.

Recent advances in gold–NHC complexes with biological properties

This tutorial review covers the recent advances made in the study of gold complexes containing N-heterocyclic carbene ligands with biological properties.

Access to divalent lanthanide NHC complexes by redox-transmetallation from silver and CO2 insertion reactions

Through a redox-transmetallation procedure, divalent NHC-LnII (NHC = N-heterocyclic carbene; Ln = Eu, Yb) complexes were obtained from the corresponding NHC-AgI. The lability of the NHC-LnII bond was investigated and treatment with CO2 led to insertion reactions without oxidation of the metal centre. The EuII complex [EuI2(IMes)(THF)3] (IMes = 1,3-dimesitylimidazol-2-ylidene) exhibits photoluminescence with a quantum yield reaching 53%.

NHC Pd(II) and Ag(I) Complexes: Synthesis, Structure, and Catalytic Activity in Three Types of C-C Coupling Reactions

Four bis-benzimidazolium salts, 1,4-bis[1'-(N-R-benzimidazoliumyl)methyl]-2,3,5,6-tetramethylbenzene 2X- (L 1 H 2 ·(PF 6 ) 2 : R = ethyl, X = PF6; L 2 H 2 ·Br 2 : R = picolyl, X = Br; L 3 H 2 ·Br 2 : R = benzyl, X = Br; and L 4 H 2 ·Br 2 : R = allyl, X = Br), and their three N-heterocyclic carbene (NHC) Pd(II) and Ag(I) complexes, L 1 Pd 2 Cl 4 (1), L 2 Ag 2 Br 2 (2), and L 4 (AgBr) 2 (3), as well as one anionic complex L 3 H 2 ·(Ag 4 Br 8 ) 0.5 (4), have been synthesized and characterized. Complex 1 adopts a funnel-like type of structure, complex 2 adopts a cyclic structure, and complex 3 is an open structure. In the crystal packing of 1-4, one-dimensional polymeric chains and two-dimensional supramolecular layers are formed via intermolecular weak interactions, including hydrogen bonds, π-π interactions, and C-H···π contacts. The catalytic activities of NHC Pd(II) complex 1 in three types of C-C coupling reactions (Suzuki-Miyaura, Heck-Mizoroki, and Sonogashira reactions) were studied. The results show that this catalytic system is efficient for these C-C coupling reactions.

New insights in Au-NHCs complexes as anticancer agents

Within the research field of antitumor metal-based agents alternative to platinum drugs, gold(I/III) coordination complexes have always been in the forefront due mainly to the familiarity of medicinal chemists with gold compounds, whose application in medicine goes back in the ancient times, and to the rich chemistry shown by this metal. In the last decade, N-heterocyclic carbene ligands (NHC), a class of ligands that largely resembles the chemical properties of phosphines, became of interest for gold(I) medicinal applications, and since then, the research on NHC-gold(I/III) coordination complexes as potential antiproliferative agents boosted dramatically. Different classes of gold(I/III)-NHC complexes often showed an outstanding in vitro antiproliferative activity, however up to now very few in vivo data have been reported to corroborate the in vitro results. This review summarizes all achievements in the field of gold (I/III) complexes comprising NHC ligands proposed as potential antiproliferative agents in the period 2004-2016, and critically analyses biological data (mainly IC₅₀ values) in relation to the chemical structures of Au compounds. The state of art of the in vivo studies so far described is also reported.